Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 6.3% during the first quarter, Holdings Channel reports. The institutional investor owned 7,395 shares of the biopharmaceutical company’s stock after buying an additional 440 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Ultragenyx Pharmaceutical were worth $842,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in RARE. AGF Investments LLC bought a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at $25,000. Valeo Financial Advisors LLC bought a new position in shares of Ultragenyx Pharmaceutical in the first quarter valued at $52,000. Captrust Financial Advisors bought a new position in shares of Ultragenyx Pharmaceutical in the fourth quarter valued at $75,000. Harvest Fund Management Co. Ltd lifted its position in shares of Ultragenyx Pharmaceutical by 15.9% during the fourth quarter. Harvest Fund Management Co. Ltd now owns 888 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 122 shares in the last quarter. Finally, Exchange Traded Concepts LLC bought a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter valued at about $182,000.
NASDAQ RARE opened at $108.62 on Thursday. The company’s 50 day moving average is $109.66 and its 200-day moving average is $129.06. Ultragenyx Pharmaceutical Inc. has a 12-month low of $65.31 and a 12-month high of $179.65. The firm has a market cap of $7.33 billion, a P/E ratio of -24.74 and a beta of 2.19.
Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, May 4th. The biopharmaceutical company reported ($2.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.25) by ($0.78). Ultragenyx Pharmaceutical had a negative net margin of 119.19% and a negative return on equity of 50.69%. The business had revenue of $99.40 million during the quarter, compared to the consensus estimate of $77.21 million. During the same period last year, the firm earned ($2.05) EPS. The business’s revenue for the quarter was up 173.7% on a year-over-year basis. As a group, equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5 earnings per share for the current fiscal year.
A number of research analysts recently weighed in on the stock. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell raised shares of Ultragenyx Pharmaceutical from a “neutral” rating to a “buy” rating and dropped their price target for the company from $160.00 to $151.00 in a research report on Wednesday, May 12th. SVB Leerink assumed coverage on shares of Ultragenyx Pharmaceutical in a research report on Sunday, May 9th. They set a “buy” rating and a $178.00 price target on the stock. TheStreet raised shares of Ultragenyx Pharmaceutical from a “d” rating to a “c-” rating in a research report on Tuesday, February 16th. Wedbush raised their price target on shares of Ultragenyx Pharmaceutical from $113.00 to $130.00 and gave the company a “neutral” rating in a research report on Friday, February 12th. Finally, Citigroup raised shares of Ultragenyx Pharmaceutical from a “neutral” rating to a “buy” rating and dropped their price target for the company from $160.00 to $151.00 in a research report on Thursday, May 6th. One analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $144.41.
In other news, Director William Aliski sold 7,500 shares of the business’s stock in a transaction that occurred on Friday, February 19th. The shares were sold at an average price of $149.01, for a total value of $1,117,575.00. Following the sale, the director now owns 73,204 shares of the company’s stock, valued at $10,908,128.04. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Camille L. Bedrosian sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, April 15th. The shares were sold at an average price of $109.09, for a total transaction of $545,450.00. Following the completion of the sale, the executive vice president now directly owns 44,139 shares in the company, valued at approximately $4,815,123.51. The disclosure for this sale can be found here. In the last three months, insiders sold 87,903 shares of company stock worth $11,201,028. Insiders own 8.20% of the company’s stock.
About Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders.
Recommended Story: Asset Allocation
Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE).